All In Biotech

Drug Trial Radar · NCT05434234

A Study of YL201 in Patients With Advanced Solid Tumors

A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

312

Planned (sponsor's estimate)

Start

May 25, 2022

Primary completion

Apr 6, 2027

Study completion Oct 6, 2027

Sponsor

Sponsor type
Industry
First posted
Jun 27, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1, multicenter, nonrandomized, open-label, first-in-human study of YL201 conducted in China and the United States. The study will include 2 parts: a dose escalation part (Part 1) followed by a dose expansion part (Part 2). Part 1 will estimate the MTD/RED(s) in dose escalation cohorts of patients with advanced solid tumors unresponsive to currently available therapies or for whom no standard therapy is available. Part 2 will include patients with selected advanced solid tumor types enrolled at the MTD/RED(s), to better define the safety profile and evaluate the efficacy of YL201.

Conditions

  • Advanced Solid Tumor

Interventions

  • YL201Drug

    Patients will be treated with YL201 intravenous (IV) infusion once every 3 weeks (Q3W) as a cycle.

  • YL201Drug

    Patients will be treated with YL201 intravenous (IV) (A mg/kg or B g/kg infusion once every 3 weeks (Q3W) as a cycle.

  • YL201 and atezolizumabDrug

    Patients will be treated with YL201 intravenous (IV) infusion (A mg/kg or B mg/kg, up to 200mg) followed by atezolizumab on day 1 of each 21 day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the occurrence of DLTs during the first cycle in Part 1Time frame: 21 days of Cycle 1
  2. Evaluate the AEs in Part 2 as characterized by type, frequency, severity, timing, seriousness and relationship to study treatmentTime frame: By the global end of trial date, approximately within 36 months
  3. Evaluate the prostate-specific antigen (PSA) response rate for patients with prostate cancer in Part 2Time frame: Approximately within 36 months
  4. Evaluate the objective response rate (ORR) for patients with solid tumors other than prostate cancer in Part 2, assessed using RECIST version 1.1Time frame: Approximately within 36 months
  5. Laboratory abnormalities as characterized by type, frequency, severity, and timing in Part 2Time frame: Biy the end of trial date, approximately within 36 months
  6. Incidence, nature, and severity of AEs graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V5.0 in Part 3Time frame: Biy the end of trial date, approximately within 36 months
  7. Nature and frequency of dose-limiting toxicities (DLTs), incidence, nature, and severity of laboratory abnormalities in Part 3Time frame: At the end of cycle 1 (each cycle is 21 days)

Locations

45 sites in 6 countries. Site status is shown where the registry gives one.

  • 002

    Fair Oaks, California · Recruiting

  • 001

    La Jolla, California · Recruiting

  • 003

    Lone Tree, Colorado · Recruiting

  • 004

    Washington D.C., District of Columbia · Recruiting

  • 005

    Boston, Massachusetts · Recruiting

  • 006

    Ann Arbor, Michigan · Recruiting

  • 007

    Detroit, Michigan · Recruiting

  • 008

    St Louis, Missouri · Recruiting

  • 009

    Santa Fe, New Mexico · Recruiting

  • 010

    New York, New York · Recruiting

  • 011

    Chapel Hill, North Carolina · Recruiting

  • 012

    Nashville, Tennessee · Recruiting

  • 014

    Houston, Texas · Recruiting

  • 015

    Irving, Texas · Recruiting

  • 013

    San Antonio, Texas · Recruiting

  • 016

    Tyler, Texas · Recruiting

  • 017

    Fairfax, Virginia · Recruiting

  • 018

    Spokane, Washington · Recruiting

  • 019

    Tacoma, Washington · Recruiting

  • 020

    Edmonton, Alberta, Canada · Recruiting

  • 021

    Kelowna, British Columbia, Canada · Recruiting

  • 022

    Brampton, Ontario, Canada · Recruiting

  • 023

    Toronto, Ontario, Canada · Recruiting

  • 024

    Guangzhou, Guangdong, China · Completed

  • 025

    Zhengzhou, Henan, China · Completed

  • 026

    Bordeaux, France · Recruiting

  • 027

    Dijon, France · Recruiting

  • 028

    Marseille, France · Recruiting

  • 029

    Nantes, France · Not yet recruiting

  • 030

    Paris, France · Not yet recruiting

  • 031

    Poitiers, France · Recruiting

  • 032

    Saint-Herblain, France · Not yet recruiting

  • 033

    Suresnes, France · Recruiting

  • 044

    Otwock, Poland · Recruiting

  • 045

    Poznan, Poland · Not yet recruiting

  • 034

    Barcelona, Barcelona, Spain · Recruiting

  • 035

    Barcelona, Barcelona, Spain · Recruiting

  • 039

    Leganés, Madrid, Spain · Not yet recruiting

  • 037

    Madrid, Madrid, Spain · Recruiting

  • 036

    Madrid, Madrid, Spain · Recruiting

Showing 40 of 45 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.